Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Introduction: Traditional factors currently used for prognostic stratification do not always adequately predict treatment response and disease evolution in advanced breast cancer patients. Therefore, the use of blood-based markers, such as circulating tumor cells (CTCs), represents a promising complementary strategy for disease monitoring. In this retrospective study, we explored the role of CTC counts as predictors of disease evolution in breast cancer patients with limited metastatic dissemination. Methods: A total of 492 advanced breast cancer patients who had a CTC count assessed by CellSearch prior to starting a new line of systemic therapy were eligible for this analysis. Using the threshold of 5 CTCs/7.5 ml of blood, pretreatment CTC counts were correlated in the overall population with metastatic site distribution, evaluated at baseline and at the time of treatment failure, using Fisher’s exact test. Time to visceral progression and time to the development of new metastatic lesions and sites were estimated in patients with nonvisceral metastases and with single-site metastatic disease, respectively, by the Kaplan-Meier method. Survival times were compared between groups according to pretreatment CTC count by logrank test. Results: In the overall population, a pretreatment level ≥5 CTCs/7.5 ml was associated with an increased baseline number of metastatic sites compared with <5 CTCs/7.5 ml (P = 0.0077). At the time of treatment failure, patients with ≥5 CTCs/7.5 ml more frequently developed new metastatic lesions and sites compared with those with <5 CTCs/7.5 ml (development of new lesions: P = 0.0002; development of new sites: P = 0.0031). Among patients with disease originally confined to nonvisceral sites, ≥5 CTCs/7.5 ml was associated with remarkably shorter time to visceral metastases (P = 0.0021) and overall survival (P = 0.0006) compared with <5 CTCs/7.5 ml. In patients with single-site metastatic disease, ≥5 CTCs/7.5 ml was associated with a significant reduction of the time to development of new metastatic sites (P = 0.0051) and new lesions (P = 0.0002) and with worse overall survival (P = 0.0101). Conclusion: Our results suggest that baseline CTC counts can be used as an early predictor of metastatic potential in breast cancer patients with limited metastatic dissemination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hellman, S., & Weichselbaum, R. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.8 · Cited by 2,562
Cited by
Antitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology
Palmirotta, R., Lovero, D., Cafforio, P., Felici, C., Mannavola, F., Pellè, E., Quaresmini, D., Tucci, M., & Silvestris, F. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918794630 · Cited by 423
Emerging tumor spheroids technologies for 3D in vitro cancer modeling
Rodrigues, T., Kundu, B., Silva-Correia, J., Kundu, S. C., Oliveira, J. M., Reis, R. L., & Correlo, V. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.018 · Cited by 178
Park, E. S., Yan, J. P., Ang, R. A., Lee, J. H., Deng, X., Duffy, S. P., Beja, K., Annala, M., Black, P. C., Chi, K. N., et al. (2018) · Lab on a Chip · doi:10.1039/c8lc00184g · Cited by 34
Yap, Y.-S., Leong, M. C., Chua, Y. W., Loh, K. W. J., Lee, G. E., Lim, E. H., Dent, R., Ng, R. C. H., Lim, J. H.-C., Singh, G., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0221305 · Cited by 23
“Results from earlier studies also suggest CTC burden as a predictor of metastatic potential, and potentially a higher visceral tumour burden [4].”
BackgroundResult
Metadata
- Authors
- Giuliano, M., Giordano, A., Jackson, S., De Giorgi, U., Mego, M., Cohen, E. N., Gao, H., Anfossi, S., Handy, B. C., Ueno, N. T., Alvarez, R. H., De Placido, S., Valero, V., Hortobagyi, G. N., Reuben, J. M., & Cristofanilli, M.
- Venue
- Breast Cancer Research
- Published
- 2014-09-16
- Volume
- 16
- Issue
- 5
- Pages
- 440-440
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2129833022
- Cited by
- 124
- References
- 1
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. https://app.cochat.ai/papers/10.1186/s13058-014-0440-8
- The paper
- Giuliano, M., Giordano, A., Jackson, S., De Giorgi, U., Mego, M., Cohen, E. N., Gao, H., Anfossi, S., Handy, B. C., Ueno, N. T., Alvarez, R. H., De Placido, S., Valero, V., Hortobagyi, G. N., Reuben, J. M., & Cristofanilli, M. (2014). Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Research. https://doi.org/10.1186/s13058-014-0440-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.